http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytoMed completes acquisition of T cell technology for China market
-
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
-
CytoMed Therapeutics secures $500,000 investment for subsidiary
-
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
-
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
-
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
-
CytoMed Therapeutics publishes research on cancer cell therapy
-
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Le
-
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
-
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
-
CytoMed completes first dose level of cancer treatment trial
-
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematolog
-
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
-
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
-
CytoMed Therapeutics (GDTC) signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited
-
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatme
-
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for tre
-
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced So
-
CytoMed Therapeutics (GDTC) first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneicCAR-T cell against blood and solid tumors received co-funding support from the NMRC Clinic
-
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-fund
-
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
-
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
-
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
-
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
-
CytoMed Therapeutics (GDTC) Acquires Cord Blood Banking Licence and Assets
-
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cance
-
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
-
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
-
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Re
-
CytoMed Therapeutics (GDTC) Granted Patent in Malaysia for Allogeneic CAR-Gamma Delta T Cell Technology
-
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
-
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
-
CytoMed Therapeutics (GDTC) Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
-
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
-
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
-
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
-
CytoMed Therapeutics (GDTC) Granted Chinese Patent for its Licensed iPSC-Based Technology
-
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
-
CytoMed Therapeutics (GDTC) Announces Chinese Patent Granted for its Licensed iPSC-Based Technology
-
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
-
CytoMed Therapeutics (GDTC) Expands Research Collaboration into China After Entering Into MOU
-
CytoMed Expands Research Collaboration into China After Entering Into MOU
-
CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit
-
CytoMed Therapeutics (GDTC) Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
-
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
-
CytoMed Therapeutics (GDTC) Granted Patent in China for Licensed Allogeneic CAR-Gamma Delta T Cell Technology
-
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
-
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
-
CytoMed Therapeutics Collaborates With The University of Texas MD Anderson Cancer Center to Advance Its Unique CAR-T Technology
